

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUNPHARMA

复星医药

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

FOSUN 复星

復星國際有限公司

FOSUN INTERNATIONAL LIMITED

(a company incorporated in Hong Kong with limited liability)

(Stock Code: 00656)

**JOINT ANNOUNCEMENT
COMPLETION OF DISCLOSEABLE TRANSACTION —
ACQUISITION OF EQUITY INTEREST IN ALMA LASERS**

This is an announcement made jointly by Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“**Fosun Pharma**”) and Fosun International Limited (“**Fosun International**”).


Unless otherwise indicated, capitalized terms used herein shall have the same meanings as defined in the joint announcement of Fosun Pharma and Fosun International dated 26 April 2013 (the “**Joint Announcement**”), in relation to, among other things, the acquisition by Sisram Medical of the equity interest in the Target Company.

A. Completion of the Acquisition

The boards of directors of Fosun Pharma and Fosun International are pleased to announce that the Acquisition was completed. As at 27 May 2013 (Israeli local time), Sisram Medical acquired 95.20% equity interest in Alma Lasers for a total consideration of US\$221.63 million. Alma Lasers is a global medical technology company that designs, develops, manufactures and markets medical and cosmetic, energy-based devices.

B. Update on Change in Share Capital of Sisram Medical

As at 27 May 2013 (Israeli local time), Ample Up, CML and Pramerica-Fosun Fund (through its wholly-owned subsidiary, Magnificent View Investments Limited (“**Magnificent View**”)) have contributed US\$44.42 million, US\$53.50 million and US\$50.00 million, respectively to Sisram Medical. Upon completion, Sisram Medical is owned as to 30.03%, 36.17% and 33.80% by Ample Up, CML and Magnificent View, respectively.



C. Management Share Option Scheme

As disclosed in the Joint Announcement, pursuant to the Share Purchase Agreement, Sisram Medical will establish the management share option scheme, through which certain share options will be granted by Sisram Medical to the existing and the newly joined management members of the Target Company. The establishment of the aforesaid management share option scheme by Sisram Medical will be subject to the approval of the shareholders of both Fosun Pharma and Fosun International. A circular containing, among other things, details regarding the proposed establishment of the management share option scheme will be dispatched to the shareholders of Fosun Pharma and Fosun International in due course.

Fosun Pharma and Fosun International will keep the shareholders and potential investors informed of any material development in connection with the Acquisition if and when necessary. Shareholders and potential investors should exercise caution when dealing in the securities of Fosun Pharma and Fosun International.

By order of the Board
**Shanghai Fosun Pharmaceutical
(Group) Co. Ltd.***
Chen Qiyu
Chairman

By order of the Board
Fosun International Limited
Guo Guangchang
Chairman

Shanghai, PRC
28 May 2013

As at the date of this announcement, the executive directors of Fosun Pharma are Mr. Chen Qiyu and Mr. Yao Fang; the non-executive directors of Fosun Pharma are Mr. Guo Guangchang, Mr. Wang Qunbin and Mr. Zhang Guozheng; and the independent non-executive directors of Fosun Pharma are Mr. Guan Yimin, Mr. Han Jiong, Dr. Zhang Weijiong and Mr. Li Man-kiu Adrian David.

As at the date of this announcement, the executive directors of Fosun International are Mr. Guo Guangchang, Mr. Liang Xinjun, Mr. Wang Qunbin, Mr. Ding Guoqi, Mr. Qin Xuetao and Mr. Wu Ping; the non-executive director of Fosun International is Mr. Fan Wei, and the independent non-executive directors of Fosun International are Mr. Zhang Shengman, Mr. Andrew Y. Yan, Mr. Zhang Huaqiao and Mr. David T. Zhang.

* for identification purposes only